Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1

Abstract Background Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication ha...

Full description

Saved in:
Bibliographic Details
Published inJournal of translational medicine Vol. 21; no. 1; pp. 1 - 549
Main Authors Chen, Ruijiao, Hao, Xiaopeng, Chen, Jingyuan, Zhang, Changyue, Fan, Huixia, Lian, Fuming, Chen, Xiaochuan, Wang, Chao, Xia, Yong
Format Journal Article
LanguageEnglish
Published London BioMed Central Ltd 16.08.2023
BioMed Central
BMC
Subjects
Antibodies
Apoptosis
Biotechnology
Bladder cancer
Cancer therapies
Carcinoma
Care and treatment
Cell adhesion & migration
Cell culture
Cell cycle
Cell growth
Cell migration
Cell proliferation
Chemotherapy
Colorectal cancer
Computer simulation
Cytotoxicity
Diagnosis
DNA biosynthesis
Drug development
Drug dosages
Fatty-acid synthase
Flow cytometry
Immunofluorescence
Invasiveness
Jorunnamycin A
Lung cancer
Medical research
Muscle invasive bladder cancer
Phosphatidylserine
Proliferation
Proteins
Proteomics
Stem cells
Toxicity
Transcriptomics
Tumors
Urological surgery
Western blotting
China
Israel
United States > US
Japan
Online AccessGet full text

Cover

Abstract Abstract Background Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication has defects, such as high toxicity, poor efficacy, and side effects. Jorunnamycin A (JorA), a natural marine compound, has been found to have a high efficiency anticancer effect, but its anticancer function and mechanism on bladder cancer have not been studied. Methods To examine the anticancer effect of JorA on MIBC, Cell Counting Kit 8, EdU staining, and colony formation analyses were performed. Moreover, a xenograft mouse model was used to verify the anticancer effect in vivo. To investigate the pharmacological mechanism of JorA, high-throughput quantitative proteomics, transcriptomics, RT-qPCR, western blotting, immunofluorescence staining, flow cytometry, pulldown assays, and molecular docking were performed. Results JorA inhibited the proliferation of MIBC cells, and the IC 50 of T24 and UM-UC-3 was 0.054 and 0.084 μM, respectively. JorA-induced significantly changed proteins were enriched in “cancer-related pathways” and “EGFR-related signaling pathways”, which mainly manifested by inhibiting cell proliferation and promoting cell apoptosis. Specifically, JorA dampened the DNA synthesis rate, induced phosphatidylserine eversion, and inhibited cell migration. Furthermore, it was discovered that fatty acid synthase (FASN) and topoisomerase 1 (TOP1) are the JorA interaction proteins. Using DockThor software, the 3D docking structures of JorA binding to FASN and TOP1 were obtained (the binding affinities were − 8.153 and − 7.264 kcal/mol, respectively). Conclusions The marine compound JorA was discovered to have a specific inhibitory effect on MIBC, and its potential pharmacological mechanism was revealed for the first time. This discovery makes an important contribution to the development of new high efficiency and low toxicity drugs for bladder cancer therapy. Graphical Abstract
AbstractList Abstract Background Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication has defects, such as high toxicity, poor efficacy, and side effects. Jorunnamycin A (JorA), a natural marine compound, has been found to have a high efficiency anticancer effect, but its anticancer function and mechanism on bladder cancer have not been studied. Methods To examine the anticancer effect of JorA on MIBC, Cell Counting Kit 8, EdU staining, and colony formation analyses were performed. Moreover, a xenograft mouse model was used to verify the anticancer effect in vivo. To investigate the pharmacological mechanism of JorA, high-throughput quantitative proteomics, transcriptomics, RT-qPCR, western blotting, immunofluorescence staining, flow cytometry, pulldown assays, and molecular docking were performed. Results JorA inhibited the proliferation of MIBC cells, and the IC 50 of T24 and UM-UC-3 was 0.054 and 0.084 μM, respectively. JorA-induced significantly changed proteins were enriched in “cancer-related pathways” and “EGFR-related signaling pathways”, which mainly manifested by inhibiting cell proliferation and promoting cell apoptosis. Specifically, JorA dampened the DNA synthesis rate, induced phosphatidylserine eversion, and inhibited cell migration. Furthermore, it was discovered that fatty acid synthase (FASN) and topoisomerase 1 (TOP1) are the JorA interaction proteins. Using DockThor software, the 3D docking structures of JorA binding to FASN and TOP1 were obtained (the binding affinities were − 8.153 and − 7.264 kcal/mol, respectively). Conclusions The marine compound JorA was discovered to have a specific inhibitory effect on MIBC, and its potential pharmacological mechanism was revealed for the first time. This discovery makes an important contribution to the development of new high efficiency and low toxicity drugs for bladder cancer therapy. Graphical Abstract
BackgroundBladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication has defects, such as high toxicity, poor efficacy, and side effects. Jorunnamycin A (JorA), a natural marine compound, has been found to have a high efficiency anticancer effect, but its anticancer function and mechanism on bladder cancer have not been studied.MethodsTo examine the anticancer effect of JorA on MIBC, Cell Counting Kit 8, EdU staining, and colony formation analyses were performed. Moreover, a xenograft mouse model was used to verify the anticancer effect in vivo. To investigate the pharmacological mechanism of JorA, high-throughput quantitative proteomics, transcriptomics, RT-qPCR, western blotting, immunofluorescence staining, flow cytometry, pulldown assays, and molecular docking were performed.ResultsJorA inhibited the proliferation of MIBC cells, and the IC50 of T24 and UM-UC-3 was 0.054 and 0.084 μM, respectively. JorA-induced significantly changed proteins were enriched in “cancer-related pathways” and “EGFR-related signaling pathways”, which mainly manifested by inhibiting cell proliferation and promoting cell apoptosis. Specifically, JorA dampened the DNA synthesis rate, induced phosphatidylserine eversion, and inhibited cell migration. Furthermore, it was discovered that fatty acid synthase (FASN) and topoisomerase 1 (TOP1) are the JorA interaction proteins. Using DockThor software, the 3D docking structures of JorA binding to FASN and TOP1 were obtained (the binding affinities were − 8.153 and − 7.264 kcal/mol, respectively).ConclusionsThe marine compound JorA was discovered to have a specific inhibitory effect on MIBC, and its potential pharmacological mechanism was revealed for the first time. This discovery makes an important contribution to the development of new high efficiency and low toxicity drugs for bladder cancer therapy.
Abstract Background Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication has defects, such as high toxicity, poor efficacy, and side effects. Jorunnamycin A (JorA), a natural marine compound, has been found to have a high efficiency anticancer effect, but its anticancer function and mechanism on bladder cancer have not been studied. Methods To examine the anticancer effect of JorA on MIBC, Cell Counting Kit 8, EdU staining, and colony formation analyses were performed. Moreover, a xenograft mouse model was used to verify the anticancer effect in vivo. To investigate the pharmacological mechanism of JorA, high-throughput quantitative proteomics, transcriptomics, RT-qPCR, western blotting, immunofluorescence staining, flow cytometry, pulldown assays, and molecular docking were performed. Results JorA inhibited the proliferation of MIBC cells, and the IC50 of T24 and UM-UC-3 was 0.054 and 0.084 μM, respectively. JorA-induced significantly changed proteins were enriched in “cancer-related pathways” and “EGFR-related signaling pathways”, which mainly manifested by inhibiting cell proliferation and promoting cell apoptosis. Specifically, JorA dampened the DNA synthesis rate, induced phosphatidylserine eversion, and inhibited cell migration. Furthermore, it was discovered that fatty acid synthase (FASN) and topoisomerase 1 (TOP1) are the JorA interaction proteins. Using DockThor software, the 3D docking structures of JorA binding to FASN and TOP1 were obtained (the binding affinities were − 8.153 and − 7.264 kcal/mol, respectively). Conclusions The marine compound JorA was discovered to have a specific inhibitory effect on MIBC, and its potential pharmacological mechanism was revealed for the first time. This discovery makes an important contribution to the development of new high efficiency and low toxicity drugs for bladder cancer therapy. Graphical Abstract
Background Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication has defects, such as high toxicity, poor efficacy, and side effects. Jorunnamycin A (JorA), a natural marine compound, has been found to have a high efficiency anticancer effect, but its anticancer function and mechanism on bladder cancer have not been studied. Methods To examine the anticancer effect of JorA on MIBC, Cell Counting Kit 8, EdU staining, and colony formation analyses were performed. Moreover, a xenograft mouse model was used to verify the anticancer effect in vivo. To investigate the pharmacological mechanism of JorA, high-throughput quantitative proteomics, transcriptomics, RT-qPCR, western blotting, immunofluorescence staining, flow cytometry, pulldown assays, and molecular docking were performed. Results JorA inhibited the proliferation of MIBC cells, and the IC.sub.50 of T24 and UM-UC-3 was 0.054 and 0.084 [mu]M, respectively. JorA-induced significantly changed proteins were enriched in "cancer-related pathways" and "EGFR-related signaling pathways", which mainly manifested by inhibiting cell proliferation and promoting cell apoptosis. Specifically, JorA dampened the DNA synthesis rate, induced phosphatidylserine eversion, and inhibited cell migration. Furthermore, it was discovered that fatty acid synthase (FASN) and topoisomerase 1 (TOP1) are the JorA interaction proteins. Using DockThor software, the 3D docking structures of JorA binding to FASN and TOP1 were obtained (the binding affinities were - 8.153 and - 7.264 kcal/mol, respectively). Conclusions The marine compound JorA was discovered to have a specific inhibitory effect on MIBC, and its potential pharmacological mechanism was revealed for the first time. This discovery makes an important contribution to the development of new high efficiency and low toxicity drugs for bladder cancer therapy. Graphical Keywords: Jorunnamycin A, Muscle invasive bladder cancer, Proteomics, Transcriptomics, Proliferation, Apoptosis, Molecular docking
BACKGROUNDBladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication has defects, such as high toxicity, poor efficacy, and side effects. Jorunnamycin A (JorA), a natural marine compound, has been found to have a high efficiency anticancer effect, but its anticancer function and mechanism on bladder cancer have not been studied.METHODSTo examine the anticancer effect of JorA on MIBC, Cell Counting Kit 8, EdU staining, and colony formation analyses were performed. Moreover, a xenograft mouse model was used to verify the anticancer effect in vivo. To investigate the pharmacological mechanism of JorA, high-throughput quantitative proteomics, transcriptomics, RT-qPCR, western blotting, immunofluorescence staining, flow cytometry, pulldown assays, and molecular docking were performed.RESULTSJorA inhibited the proliferation of MIBC cells, and the IC50 of T24 and UM-UC-3 was 0.054 and 0.084 μM, respectively. JorA-induced significantly changed proteins were enriched in "cancer-related pathways" and "EGFR-related signaling pathways", which mainly manifested by inhibiting cell proliferation and promoting cell apoptosis. Specifically, JorA dampened the DNA synthesis rate, induced phosphatidylserine eversion, and inhibited cell migration. Furthermore, it was discovered that fatty acid synthase (FASN) and topoisomerase 1 (TOP1) are the JorA interaction proteins. Using DockThor software, the 3D docking structures of JorA binding to FASN and TOP1 were obtained (the binding affinities were - 8.153 and - 7.264 kcal/mol, respectively).CONCLUSIONSThe marine compound JorA was discovered to have a specific inhibitory effect on MIBC, and its potential pharmacological mechanism was revealed for the first time. This discovery makes an important contribution to the development of new high efficiency and low toxicity drugs for bladder cancer therapy.
Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality. There is an urgent need to develop new drugs with low toxicity and high efficiency for MIBC because existing medication has defects, such as high toxicity, poor efficacy, and side effects. Jorunnamycin A (JorA), a natural marine compound, has been found to have a high efficiency anticancer effect, but its anticancer function and mechanism on bladder cancer have not been studied. To examine the anticancer effect of JorA on MIBC, Cell Counting Kit 8, EdU staining, and colony formation analyses were performed. Moreover, a xenograft mouse model was used to verify the anticancer effect in vivo. To investigate the pharmacological mechanism of JorA, high-throughput quantitative proteomics, transcriptomics, RT-qPCR, western blotting, immunofluorescence staining, flow cytometry, pulldown assays, and molecular docking were performed. JorA inhibited the proliferation of MIBC cells, and the IC.sub.50 of T24 and UM-UC-3 was 0.054 and 0.084 [mu]M, respectively. JorA-induced significantly changed proteins were enriched in "cancer-related pathways" and "EGFR-related signaling pathways", which mainly manifested by inhibiting cell proliferation and promoting cell apoptosis. Specifically, JorA dampened the DNA synthesis rate, induced phosphatidylserine eversion, and inhibited cell migration. Furthermore, it was discovered that fatty acid synthase (FASN) and topoisomerase 1 (TOP1) are the JorA interaction proteins. Using DockThor software, the 3D docking structures of JorA binding to FASN and TOP1 were obtained (the binding affinities were - 8.153 and - 7.264 kcal/mol, respectively). The marine compound JorA was discovered to have a specific inhibitory effect on MIBC, and its potential pharmacological mechanism was revealed for the first time. This discovery makes an important contribution to the development of new high efficiency and low toxicity drugs for bladder cancer therapy.
ArticleNumber 549
Audience Academic
Author Zhang, Changyue
Xia, Yong
Wang, Chao
Fan, Huixia
Chen, Ruijiao
Lian, Fuming
Chen, Xiaochuan
Hao, Xiaopeng
Chen, Jingyuan
Author_xml – sequence: 1
  fullname: Chen, Ruijiao
– sequence: 2
  fullname: Hao, Xiaopeng
– sequence: 3
  fullname: Chen, Jingyuan
– sequence: 4
  fullname: Zhang, Changyue
– sequence: 5
  fullname: Fan, Huixia
– sequence: 6
  fullname: Lian, Fuming
– sequence: 7
  fullname: Chen, Xiaochuan
– sequence: 8
  fullname: Wang, Chao
– sequence: 9
  fullname: Xia, Yong
BookMark eNptkt9qFDEUxgepYFt9Aa8C3ngzNf8mmVzJUqyuFCtYr0OSOTNmmUnWZGZhH6FvbbZb1BUJIeHkO7-Tj3MuqrMQA1TVa4KvCGnFu0yoErLGlNWYc4xr9qw6J1yqummlOPvr_qK6yHmDMeUNV-fVwzrMMCQzQ4emZZx9HSfvMjLBjPsMGSXYgRnR55iWEMy0dz6gFTJFgULcwYjyst0myDkm1Jc9LdmNUPuwM9nvANnRdB0k5Exw5bB7NJs0wOzDgG5W376USh26v_tKXlbPezNmePV0Xlbfbz7cX3-qb-8-rq9Xt7Xjis61FZwQ6TgIaqQQQvaqJdbZjhMLkjdAoZctM40kwjiqmpZ0jDdMgVJOCswuq_WR20Wz0dvkJ5P2OhqvHwMxDdqk2RcTGoyl0nUW415xR5R1QknrmGx627c9K6z3R9Z2sRN0DsKczHgCPX0J_oce4k4TzGlbnBTC2ydCij8XyLOefHYwjiZAXLKmbUMFK-06FHvzj3QTl1T6dFRRpQjHf1SDKQ586GMp7A5QvZKCUNzi9sC6-o-qrA5K-8ts9b7ETxLoMcGlmHOC_rdJgvVhBPVxBHX5qX4cQc3YL3rk0MM
Cites_doi 10.1101/gr.209643.116
10.3322/caac.21631
10.1007/s00345-019-02984-4
10.3390/biom5031652
10.1111/j.1464-410X.2012.11762.x
10.1093/neuonc/nox191
10.3389/fcell.2021.709498
10.1155/2021/1377989
10.1016/j.chembiol.2010.04.012
10.1038/s43018-021-00184-x
10.3389/fonc.2021.667212
10.1002/1878-0261.12155
10.1186/1471-2407-14-292
10.1038/s41598-021-84700-0
10.1016/j.cellsig.2020.109709
10.1038/s41585-020-00404-6
10.1126/scitranslmed.abb6731
10.1186/s12943-019-1090-3
10.1016/j.gene.2015.07.031
10.1016/bs.acc.2021.07.005
10.2174/1389450115666141120112818
10.1080/14728222.2017.1381087
10.3390/jcm11010203
10.1517/14728222.2014.945427
10.1016/j.phrs.2021.105583
10.3389/fphar.2018.01045
10.1158/1078-0432.CCR-15-0126
10.1124/jpet.119.258947
10.1097/CCO.0b013e328331a7a4
10.3390/cancers10080262
10.3390/md19050261
10.1038/nm.3388
10.1158/0008-5472.CAN-16-2320
10.1038/s41419-019-2203-z
10.1038/s41585-019-0208-0
10.1038/s41467-018-08074-0
10.1021/acs.jnatprod.6b00433
10.1016/j.lungcan.2010.05.015
10.1038/s41571-021-00558-1
10.1158/1078-0432.CCR-19-1089
10.1038/s41467-020-17871-5
10.1021/acs.jnatprod.9b00102
10.1021/np400538q
ContentType Journal Article
Copyright COPYRIGHT 2023 BioMed Central Ltd.
2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
BioMed Central Ltd., part of Springer Nature 2023
Copyright_xml – notice: COPYRIGHT 2023 BioMed Central Ltd.
– notice: 2023. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: BioMed Central Ltd., part of Springer Nature 2023
DBID AAYXX
CITATION
3V.
7T5
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
COVID
DWQXO
FYUFA
GHDGH
H94
K9.
M0S
M1P
PIMPY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s12967-023-04400-3
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
AIDS and Cancer Research Abstracts
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
PML(ProQuest Medical Library)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
Coronavirus Research Database
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
AIDS and Cancer Research Abstracts
Immunology Abstracts
ProQuest One Academic
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
Publicly Available Content Database


MEDLINE - Academic
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1479-5876
EndPage 549
ExternalDocumentID oai_doaj_org_article_eab27cdb00f94c19bc697bc375fbf8f3
A761208083
10_1186_s12967_023_04400_3
GeographicLocations China
Israel
United States--US
Japan
GeographicLocations_xml – name: China
– name: Israel
– name: United States--US
– name: Japan
GrantInformation_xml – fundername: ;
  grantid: tsqn201909147
– fundername: ;
  grantid: 21807041; 82172978
– fundername: ;
  grantid: JYHL2022ZD04
– fundername: ;
  grantid: 2060302
GroupedDBID ---
-A0
0R~
29L
2WC
3V.
53G
5VS
6PF
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AAWTL
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ACIHN
ACIWK
ACPRK
ACRMQ
ADBBV
ADINQ
ADUKV
AEAQA
AENEX
AFKRA
AFPKN
AFRAH
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AMTXH
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C24
C6C
CCPQU
CITATION
CS3
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
HMCUK
HYE
IAO
IHR
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SBL
SOJ
TR2
TUS
UKHRP
WOQ
WOW
XSB
~8M
ABVAZ
AFGXO
AFNRJ
7T5
7XB
8FK
AZQEC
COVID
DWQXO
H94
K9.
PQEST
PQUKI
7X8
5PM
ID FETCH-LOGICAL-c492t-b64117c4e62a76667f981bcbd41be745e2ef783a5716ac29581d34539e99c7603
IEDL.DBID RPM
ISSN 1479-5876
IngestDate Tue Oct 22 15:13:23 EDT 2024
Tue Sep 17 21:29:33 EDT 2024
Fri Oct 25 06:37:21 EDT 2024
Thu Oct 10 17:27:52 EDT 2024
Thu Feb 22 23:42:39 EST 2024
Fri Feb 02 04:40:22 EST 2024
Thu Sep 12 18:07:09 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c492t-b64117c4e62a76667f981bcbd41be745e2ef783a5716ac29581d34539e99c7603
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-3482-9138
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428641/
PQID 2852299140
PQPubID 43076
ParticipantIDs doaj_primary_oai_doaj_org_article_eab27cdb00f94c19bc697bc375fbf8f3
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10428641
proquest_miscellaneous_2852630023
proquest_journals_2852299140
gale_infotracmisc_A761208083
gale_infotracacademiconefile_A761208083
crossref_primary_10_1186_s12967_023_04400_3
PublicationCentury 2000
PublicationDate 2023-08-16
PublicationDateYYYYMMDD 2023-08-16
PublicationDate_xml – month: 08
  year: 2023
  text: 2023-08-16
  day: 16
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
PublicationTitle Journal of translational medicine
PublicationYear 2023
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References F Wilson (4400_CR3) 2022; 107
LE Lupien (4400_CR13) 2019; 371
HM Huang (4400_CR31) 2021; 11
KE Carlstrom (4400_CR25) 2020; 11
RF Dong (4400_CR20) 2021; 167
Y Xu (4400_CR39) 2015; 5
D Jiang (4400_CR6) 2021; 18
K Wenzl (4400_CR36) 2015; 16
S Sumkhemthong (4400_CR9) 2021; 19
V Fendrich (4400_CR12) 2014; 18
VG Patel (4400_CR1) 2020; 70
FW Schmitges (4400_CR30) 2016; 26
H Taniguchi (4400_CR22) 2019; 10
AJA Deutsch (4400_CR35) 2017; 77
H Yang (4400_CR37) 2021; 2021
MP Patel (4400_CR23) 2009; 21
LR Hardy (4400_CR27) 2018; 10
S Sigismund (4400_CR15) 2018; 12
N Sirimangkalakitti (4400_CR7) 2016; 79
N Karimianpour (4400_CR42) 2008; 5
R Chen (4400_CR10) 2013; 76
A Thomas (4400_CR40) 2019; 25
E Eskilsson (4400_CR17) 2018; 20
S Afreen (4400_CR24) 2020; 11
ZL Smith (4400_CR5) 2013; 112
PJ Yue (4400_CR34) 2020; 74
JA Menendez (4400_CR44) 2017; 21
GAU Ecoy (4400_CR8) 2019; 82
CR Chong (4400_CR16) 2013; 19
E Laack (4400_CR19) 2010; 69
S Fu (4400_CR33) 2018; 9
SF Jones (4400_CR41) 2015; 21
IA Guedes (4400_CR11) 2021; 11
C Alifrangis (4400_CR14) 2019; 16
T Di Palma (4400_CR26) 2014; 14
CJ Zhu (4400_CR21) 2019; 18
A Ul Kabir (4400_CR32) 2021; 13
A Friedlaender (4400_CR18) 2022; 19
CX Zhang (4400_CR28) 2021; 9
Y Pommier (4400_CR38) 2010; 17
S Mukhopadhyay (4400_CR43) 2021; 2
JM Pei (4400_CR29) 2015; 573
A Richters (4400_CR2) 2020; 38
M Racioppi (4400_CR4) 2021; 11
References_xml – volume: 26
  start-page: 1742
  year: 2016
  ident: 4400_CR30
  publication-title: Genome Res
  doi: 10.1101/gr.209643.116
  contributor:
    fullname: FW Schmitges
– volume: 70
  start-page: 404
  year: 2020
  ident: 4400_CR1
  publication-title: Ca-Cancer J Clin
  doi: 10.3322/caac.21631
  contributor:
    fullname: VG Patel
– volume: 38
  start-page: 1895
  year: 2020
  ident: 4400_CR2
  publication-title: World J Urol
  doi: 10.1007/s00345-019-02984-4
  contributor:
    fullname: A Richters
– volume: 5
  start-page: 1652
  year: 2015
  ident: 4400_CR39
  publication-title: Biomolecules
  doi: 10.3390/biom5031652
  contributor:
    fullname: Y Xu
– volume: 112
  start-page: 13
  year: 2013
  ident: 4400_CR5
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2012.11762.x
  contributor:
    fullname: ZL Smith
– volume: 20
  start-page: 743
  year: 2018
  ident: 4400_CR17
  publication-title: Neuro Oncol
  doi: 10.1093/neuonc/nox191
  contributor:
    fullname: E Eskilsson
– volume: 9
  year: 2021
  ident: 4400_CR28
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2021.709498
  contributor:
    fullname: CX Zhang
– volume: 2021
  start-page: 1377989
  year: 2021
  ident: 4400_CR37
  publication-title: J Oncol
  doi: 10.1155/2021/1377989
  contributor:
    fullname: H Yang
– volume: 17
  start-page: 421
  year: 2010
  ident: 4400_CR38
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2010.04.012
  contributor:
    fullname: Y Pommier
– volume: 2
  start-page: 271
  year: 2021
  ident: 4400_CR43
  publication-title: Nat Cancer
  doi: 10.1038/s43018-021-00184-x
  contributor:
    fullname: S Mukhopadhyay
– volume: 11
  year: 2021
  ident: 4400_CR31
  publication-title: Front Oncol
  doi: 10.3389/fonc.2021.667212
  contributor:
    fullname: HM Huang
– volume: 12
  start-page: 3
  year: 2018
  ident: 4400_CR15
  publication-title: Mol Oncol
  doi: 10.1002/1878-0261.12155
  contributor:
    fullname: S Sigismund
– volume: 14
  start-page: 292
  year: 2014
  ident: 4400_CR26
  publication-title: BMC Cancer
  doi: 10.1186/1471-2407-14-292
  contributor:
    fullname: T Di Palma
– volume: 11
  start-page: 5543
  year: 2021
  ident: 4400_CR11
  publication-title: Sci Rep
  doi: 10.1038/s41598-021-84700-0
  contributor:
    fullname: IA Guedes
– volume: 74
  year: 2020
  ident: 4400_CR34
  publication-title: Cell Signal
  doi: 10.1016/j.cellsig.2020.109709
  contributor:
    fullname: PJ Yue
– volume: 18
  start-page: 104
  year: 2021
  ident: 4400_CR6
  publication-title: Nat Rev Urol
  doi: 10.1038/s41585-020-00404-6
  contributor:
    fullname: D Jiang
– volume: 13
  year: 2021
  ident: 4400_CR32
  publication-title: Sci Transl Med.
  doi: 10.1126/scitranslmed.abb6731
  contributor:
    fullname: A Ul Kabir
– volume: 18
  start-page: 153
  year: 2019
  ident: 4400_CR21
  publication-title: Mol Cancer
  doi: 10.1186/s12943-019-1090-3
  contributor:
    fullname: CJ Zhu
– volume: 573
  start-page: 91
  year: 2015
  ident: 4400_CR29
  publication-title: Gene
  doi: 10.1016/j.gene.2015.07.031
  contributor:
    fullname: JM Pei
– volume: 107
  start-page: 265
  year: 2022
  ident: 4400_CR3
  publication-title: Adv Clin Chem
  doi: 10.1016/bs.acc.2021.07.005
  contributor:
    fullname: F Wilson
– volume: 16
  start-page: 38
  year: 2015
  ident: 4400_CR36
  publication-title: Curr Drug Targets
  doi: 10.2174/1389450115666141120112818
  contributor:
    fullname: K Wenzl
– volume: 21
  start-page: 1001
  year: 2017
  ident: 4400_CR44
  publication-title: Expert Opin Ther Tar
  doi: 10.1080/14728222.2017.1381087
  contributor:
    fullname: JA Menendez
– volume: 11
  start-page: 203
  year: 2021
  ident: 4400_CR4
  publication-title: J Clin Med
  doi: 10.3390/jcm11010203
  contributor:
    fullname: M Racioppi
– volume: 18
  start-page: 1277
  year: 2014
  ident: 4400_CR12
  publication-title: Expert Opin Ther Tar
  doi: 10.1517/14728222.2014.945427
  contributor:
    fullname: V Fendrich
– volume: 167
  year: 2021
  ident: 4400_CR20
  publication-title: Pharmacol Res
  doi: 10.1016/j.phrs.2021.105583
  contributor:
    fullname: RF Dong
– volume: 9
  start-page: 1045
  year: 2018
  ident: 4400_CR33
  publication-title: Front Pharmacol
  doi: 10.3389/fphar.2018.01045
  contributor:
    fullname: S Fu
– volume: 21
  start-page: 5434
  year: 2015
  ident: 4400_CR41
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-15-0126
  contributor:
    fullname: SF Jones
– volume: 371
  start-page: 171
  year: 2019
  ident: 4400_CR13
  publication-title: J Pharmacol Exp Ther
  doi: 10.1124/jpet.119.258947
  contributor:
    fullname: LE Lupien
– volume: 21
  start-page: 516
  year: 2009
  ident: 4400_CR23
  publication-title: Curr Opin Oncol
  doi: 10.1097/CCO.0b013e328331a7a4
  contributor:
    fullname: MP Patel
– volume: 10
  start-page: 262
  year: 2018
  ident: 4400_CR27
  publication-title: Cancers
  doi: 10.3390/cancers10080262
  contributor:
    fullname: LR Hardy
– volume: 5
  start-page: 237
  year: 2008
  ident: 4400_CR42
  publication-title: Urol J
  contributor:
    fullname: N Karimianpour
– volume: 19
  start-page: 261
  year: 2021
  ident: 4400_CR9
  publication-title: Mar Drugs
  doi: 10.3390/md19050261
  contributor:
    fullname: S Sumkhemthong
– volume: 19
  start-page: 1389
  year: 2013
  ident: 4400_CR16
  publication-title: Nat Med
  doi: 10.1038/nm.3388
  contributor:
    fullname: CR Chong
– volume: 77
  start-page: 2375
  year: 2017
  ident: 4400_CR35
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-16-2320
  contributor:
    fullname: AJA Deutsch
– volume: 11
  start-page: 8
  year: 2020
  ident: 4400_CR24
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-019-2203-z
  contributor:
    fullname: S Afreen
– volume: 16
  start-page: 465
  year: 2019
  ident: 4400_CR14
  publication-title: Nat Rev Urol
  doi: 10.1038/s41585-019-0208-0
  contributor:
    fullname: C Alifrangis
– volume: 10
  start-page: 259
  year: 2019
  ident: 4400_CR22
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-08074-0
  contributor:
    fullname: H Taniguchi
– volume: 79
  start-page: 2089
  year: 2016
  ident: 4400_CR7
  publication-title: J Nat Prod
  doi: 10.1021/acs.jnatprod.6b00433
  contributor:
    fullname: N Sirimangkalakitti
– volume: 69
  start-page: 259
  year: 2010
  ident: 4400_CR19
  publication-title: Lung Cancer
  doi: 10.1016/j.lungcan.2010.05.015
  contributor:
    fullname: E Laack
– volume: 19
  start-page: 51
  year: 2022
  ident: 4400_CR18
  publication-title: Nat Rev Clin Oncol
  doi: 10.1038/s41571-021-00558-1
  contributor:
    fullname: A Friedlaender
– volume: 25
  start-page: 6581
  year: 2019
  ident: 4400_CR40
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-19-1089
  contributor:
    fullname: A Thomas
– volume: 11
  start-page: 4071
  year: 2020
  ident: 4400_CR25
  publication-title: Nat Commun
  doi: 10.1038/s41467-020-17871-5
  contributor:
    fullname: KE Carlstrom
– volume: 82
  start-page: 1861
  year: 2019
  ident: 4400_CR8
  publication-title: J Nat Prod
  doi: 10.1021/acs.jnatprod.9b00102
  contributor:
    fullname: GAU Ecoy
– volume: 76
  start-page: 1789
  year: 2013
  ident: 4400_CR10
  publication-title: J Nat Prod
  doi: 10.1021/np400538q
  contributor:
    fullname: R Chen
SSID ssj0024549
Score 2.4157784
Snippet Abstract Background Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma...
Background Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high...
Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high mortality....
BackgroundBladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high...
BACKGROUNDBladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma with high...
Abstract Background Bladder cancer is a urological carcinoma with high incidence, among which muscle invasive bladder cancer (MIBC) is a malignant carcinoma...
SourceID doaj
pubmedcentral
proquest
gale
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 1
SubjectTerms Antibodies
Apoptosis
Biotechnology
Bladder cancer
Cancer therapies
Carcinoma
Care and treatment
Cell adhesion & migration
Cell culture
Cell cycle
Cell growth
Cell migration
Cell proliferation
Chemotherapy
Colorectal cancer
Computer simulation
Cytotoxicity
Diagnosis
DNA biosynthesis
Drug development
Drug dosages
Fatty-acid synthase
Flow cytometry
Immunofluorescence
Invasiveness
Jorunnamycin A
Lung cancer
Medical research
Muscle invasive bladder cancer
Phosphatidylserine
Proliferation
Proteins
Proteomics
Stem cells
Toxicity
Transcriptomics
Tumors
Urological surgery
Western blotting
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1BaxUxEA7SQ_EiWhWfVokgeJDQl2w22Ryf0kcttAq20FtIsgkW6m7Zfa_Qn-C_dia7W7r24MXrZjbJZiYz37CTL4R8UCmqBB6RJSkFk7pMzChpmHMO4HKKIgQ84Hxyqo7O5fFFeXHvqi-sCRvogYeFO4jOCx1qsI5kZODGB2W0DwX06lOVBp7PpZmSqYllD9Ke6YhMpQ56iGrgECA-MbxiGTzPLAxltv6HPvnvOsl7gWf9lDwZESNdDTN9Rh7FZo_snoz_xJ-T318nxoea5vJAhgeNe-oy3UjsKZI0QQfHbQdg1f26hdfoijqQoE17E69ov73O5bBtRwHCQic9DMQumxuHte3UX6F36mhAA-mov6VD-TgEPbpe_TiFkWp69u07f0HO14dnX47YeMECC9KIDfNKcq6DjEo4DXmMTgZQbPC15D5qWUYRk64KV0JS5YIwJYDbQpaFicYErZbFS7LTtE18RajQ3DsJaEk5L33Cn7HGJOlULZUreLkgn6b1ttcDj4bN-Uel7KAdC9qxWTu2WJDPqJI7SeTAzg_AMuxoGfZflrEgH1GhFncqqC-48cABTBg5r-xKA7oDwFyB5P5MEnZYmDdPJmHHHd5bUQFyBXAtlwvy_q4Z38SqtSa220EGKc0EdFHNTGn2ZfOW5vJnZvnmmM2Cgl7_j7V4Qx6LbP0V42qf7Gy6bXwLaGrj3-WN8weGXh9D
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Coronavirus Research Database
  dbid: COVID
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Nb9QwELVgKyEufCMWCjISEgfktnEcOz6hpbBqK7VFokW9WbZjQ0VJlmS3UvkH_GvGjtOSInHgGk_sRDOeeWOPnxF6xb3jHjwi8YxRwkThieRMEq01wGXvqLXhgPP-Ad85ZnsnxUlacOtSWeXgE6Ojrhob1sg3aQlIAcAM23q7-EHCrVFhdzVdoXETreXQXk7Q2vbh5933V2x7kP4MR2VKvtlBdAPHAHGKhKuWwQONwlFk7f_bN1-vl_wjAM3vIjV8el938m1jtTQb9uc1Vsf__7d76E7CpnjWG9N9dMPVD9Ct_bT7_hD92h24JSocCxFJONLcYR2JTVyHAx0UdLDXtACL9fcLeA3PsAYJXDfn7gx3q0UsvG1aDGAZOulgIHJan-tQRY_NWfCDLbbBFFtsLnBfqA7hFc9nnw5gpAofHX7MHqHj-Yej7R2SrnIglkm6JIazLBOWOU61gIxJeAl42ZqKZcYJVjjqvChzXUD6pi2VBcDonBW5dFJawbfyx2hSN7V7gjAVmdEMcBnXhhkftn2l9EzzinGdZ8UUvRk0qhY9Y4eKmU7JVa9_BfpXUf8qn6J3QemXkoFtOz5o2i8qTV7ltKHCVuChvGQ2k8ZyKYzNwbKNLz108jqYjAo-AQzE6nS0AT44sGupmQAcCdC8BMn1kSTMZTtuHgxEJV_SqSvrmKKXl83hzVAfV7tm1csE8jQKXZQjYx392bilPv0a-cSzkDeDgp7-e_Rn6DaNM6ckGV9Hk2W7cs8BkS3NizTtfgP21jls
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELZKkRAXxFMsLchISByQoXEmdnxAaEGsSqUWJLpSb5bttUulJWmT3Yr9Cfxrxk5SCPTAdT2ZbDKvb5TxZ0JeiOBFwIzIAgBnIIvAlADFjDEIl4PnzsUNzodHYn8OByfFyRYZjjvqX2B7bWsXz5OaN8vXPy427zDg36aAL8WbFmsWhjtWHxYPUMa8coPc5ICdehzlg_I3916R4HAGUrEC08CwieZaHaNClfj8_83af09S_lGaZnfJnR5T0mnnBPfIlq_uk1uH_VfzB-Tnp4ETYkHTACGLW5FbahIhiW9ppHFCBQd1g3DWfN_gZXRKDUrQqr70S9quz9PAbN1QBLmopMUbsbPq0sTpd2qXMX811EUXaqjd0G7AHMsinU2_HuGdFvT485fsIZnPPh5_2Gf9EQzMgeIrZgVkmXTgBTcSOx0ZFOJcZxeQWS-h8NwHWeamwLbLOK4KhL85FLnySjkp9vJHZLuqK_-YUC4zawDxlDAWbIifa5UKYMQChMmzYkJeDe9bn3dMGzp1KKXQnXU0Wkcn6-h8Qt5Hk1xJRpbs9EPdnOo-6LQ3lku3wMwSFLhMWSeUtC5Hj7ShDKjkZTSojt6F5nOm35KAfziyYumpRPyHkLpEyd2RJMagGy8PLqEHF9a8RGyL8Bv2JuT51XK8Ms61Vb5edzKR9IyjinLkSqMnG69UZ98SD3gW-1000JP_fowdcpsnFy9ZJnbJ9qpZ-6cIqlb2WYqUX1RbHkk
  priority: 102
  providerName: Scholars Portal
Title Integrated multi-omics analyses reveal Jorunnamycin A as a novel suppressor for muscle-invasive bladder cancer by targeting FASN and TOP1
URI https://www.proquest.com/docview/2852299140
https://search.proquest.com/docview/2852630023
https://pubmed.ncbi.nlm.nih.gov/PMC10428641
https://doaj.org/article/eab27cdb00f94c19bc697bc375fbf8f3
Volume 21
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swEBZtB2MvYz9Zti5oMNjDcFPLsmQ9JllDW0gaunaEvQhJlrZAYgc7KfRP2H-9k2KXeXvbiwPRSXZ8p7vv4rvPCH1kzjIHHjFylJKI8tRFglERKaUALjtLjPENztMZO7-ll4t0cYBY2wsTivaNXp4Uq_VJsfwZais3azNo68QG8-k49kCf0XhwiA7BQtscvWXYg5SnbY_J2KCGiAbOAGJT5F-vDF6nE4ICU_-__vjvGsk_gs7kGXraoEU83F_Vc3Rgixfo8bR5Hv4S_bpo2R5yHEoDI99kXGMVqEZsjT1BEyxwWVYAVNX6HqbhIVYggYvyzq5wvduEUtiywgBfYZEaThQtizvl69qxXnnPVGHjjaPC-h7vS8ch4OHJ8OsMzpTjm6t5_ArdTs5uxudR83KFyFBBtpGG-xdzQy0jikMOw50ABGt0TmNtOU0tsY5niUohoVKGiBSAbULTRFghDGenyWt0VJSFfYMw4bFWFJASU5pq5x_ECuGoYjllKonTHvrc3m-52XNoyJB7ZEzutSNBOzJoRyY9NPIqeZD0_Nfhi7L6IRsrkFZpwk0OPsMJamKhDRNcmwRsTbvMwSKfvEKl36WgPqOaZgO4YM93JYcckB2A5QwkjzuSsLtMd7g1Cdns7lqSDFArAGt62kMfHob9TF-xVthyt5fxdGYElsg6ptT5Zd0RMPjA8N0a-Nv_n_oOPSHB5rMoZsfoaFvt7HvAT1vdh02z4H30aHQ2m1_D5_jq28WXfvg3Ao5TmsHxevS9H7bVbwUQI6s
link.rule.ids 230,315,730,783,787,867,888,2109,12068,21400,24330,27936,27937,31731,31732,33756,33757,38528,43322,43817,43907,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELaglYAL74qFAkZC4oDcbhzHjk9oKax2S3eLxBb1ZtmODRUlWZLdSuUf8K8Z59GSInHgGk_sRDOe-cYef0boJfeOe_CIxDNGCROJJ5IzSbTWAJe9o9aGA86zOZ8csf3j5LhdcKvassrOJ9aOOitsWCPfpSkgBQAzbPhm-YOEW6PC7mp7hcZ1tAmBdQjJ1-be4efpu0u2PUh_uqMyKd-tILqBY4A4RcJVy-CBeuGoZu3_2zdfrZf8IwCN7yDVfXpTd_JtZ70yO_bnFVbH__-3u-h2i03xqDGme-iay--jG7N29_0B-jXtuCUyXBciknCkucK6JjZxFQ50UNDBflECLNbfz-E1PMIaJHBenLlTXK2XdeFtUWIAy9BJBQORk_xMhyp6bE6DHyyxDaZYYnOOm0J1CK94PPo0h5EyvDj8GD1ER-P3i70Jaa9yIJZJuiKGsygSljlOtYCMSXgJeNmajEXGCZY46rxIY51A-qYtlQnA6JglsXRSWsGH8RbayIvcPUKYishoBriMa8OMD9u-Unqmeca4jqNkgF53GlXLhrFD1ZlOylWjfwX6V7X-VTxAb4PSLyQD23b9oCi_qHbyKqcNFTYDD-Uls5E0lkthbAyWbXzqoZNXwWRU8AlgIFa3RxvggwO7lhoJwJEAzVOQ3O5Jwly2_ebOQFTrSyp1aR0D9OKiObwZ6uNyV6wbmUCeRqGLtGesvT_rt-QnX2s-8SjkzaCgx_8e_Tm6OVnMDtTBdP7hCbpF61mUkohvo41VuXZPAZ2tzLN2Cv4GvIQ8Uw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLVgSBMvfCMKA4yExANy2ySOHT-WQbUNWiqxSZN4sGzHhoo2qZJ20vgH_GuunWQi422v8bUT617feywfnyD0ljnLHGRE4iiNCeWpI4JRQZRSAJedjY3xF5xnc3Z0Rk_O0_OWVVm3tMrC6OWwWK2HxfJn4FZu1mbU8cRGi9lh5IE-o9Fok7vRbXQHFu2YdTv1TmcPNj7dJZmMjWqoa5ASoEIR_5NlyD29QhT0-v_PyteZkv-Unul99L376IZx8mu42-qh-X1Nz_Fms3qA7rWIFE8am4foli0eof1Ze-b-GP057hQlchzoh8RfZK6xCnImtsZeBAoGOCkrAMNqfQnd8AQrsMBFeWFXuN5tAt22rDBAZBikhheRZXGhPHce65XPfhU2PgArrC9xQ0-Hooqnk29zeFOOT78uoifobPrp9PCItD9wIIaKeEs0zCbihloWKw77JO4EoGSjcxppy2lqY-t4lqgUNm3KxCIF8JzQNBFWCMPZOHmK9oqysM8QjnmkFQU0xpSm2vnDXiEcVSynTCVROkDvO2_KTaPTIcP-JmOy8b0E38vge5kM0Afv8CtLr7EdHpTVD9n6RFqlY25yyEtOUBMJbZjg2iQQz9plDgZ558NF-kwAwWFUe6EBPthraskJB_QIgDwDy4OeJaxg02_uAk62GaSWcQbIGMA7HQ_Qm6tm39Oz4gpb7hobL5kWwxBZL1B7M-u3QPgFFfEu3J7fvOtrtL_4OJVfjuefX6C7cVhcGYnYAdrbVjv7EuDaVr8K6_IvwiBBVQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Integrated+multi-omics+analyses+reveal+Jorunnamycin+A+as+a+novel+suppressor+for+muscle-invasive+bladder+cancer+by+targeting+FASN+and+TOP1&rft.jtitle=Journal+of+translational+medicine&rft.au=Chen%2C+Ruijiao&rft.au=Hao%2C+Xiaopeng&rft.au=Chen%2C+Jingyuan&rft.au=Zhang%2C+Changyue&rft.date=2023-08-16&rft.pub=BioMed+Central+Ltd&rft.issn=1479-5876&rft.eissn=1479-5876&rft.volume=21&rft.issue=1&rft_id=info:doi/10.1186%2Fs12967-023-04400-3&rft.externalDocID=A761208083
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1479-5876&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1479-5876&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1479-5876&client=summon